Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Oncology Sales Take Off As Veklury’s Come Down To Earth

Q2 Saw Cancer Drug Sales Up 71%

Executive Summary

As expected, the COVID-19 drug’s sales fell significantly, though it remains in frequent use among hospitalized patients. Meanwhile, oncology drug sales broke the half billion-dollar mark.

You may also be interested in...



IDWeek 2022 Notebook: Entasis Bolsters Case For SUL-DUR Antibiotic Combo

Entasis is hoping for a pathogen- rather than location-specific indication for sulbactam-durlobactam (SUL-DUR) in the US. Gilead’s Veklury remains a standard-of-care COVID-19 treatment. Summit claims further analysis of failed ridinilazole Phase III study shows recurrence advantage versus vancomycin.

Gilead Gets Lenacapavir To EU Approval For HIV Salvage Therapy, Awaits FDA’s Call

A first-in-class capsid inhibitor, lenacapavir is a linchpin of Gilead’s long-term strategy in HIV treatment and prevention, but has faced regulatory setbacks in the US.

Frontier Bets $52m On Potential Rival To Gilead's Veklury

Frontier Biotechnologies is seeking to enroll roughly 1,200 hospitalized COVID patients in an international Phase II/III clinical trial to evaluate its bofutrelvir (FB2001) in competition with Gilead’s Veklury.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel